SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.
| Revenue (Most Recent Fiscal Year) | $1.00M |
| Net Income (Most Recent Fiscal Year) | $-30.88M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -132.51% |
| Return on Assets (Trailing 12 Months) | -92.79% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.91 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.50 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 125.08M |
| Free Float | 123.58M |
| Market Capitalization | $267.67M |
| Average Volume (Last 20 Days) | 3.41M |
| Beta (Past 60 Months) | 2.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 17.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |